Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on the Company’s web site at www.oncopeptides.com. The company’s CEO Jakob Lindbe... read more

– Preliminary data from FIERCE-21 Phase 2 trial highlighted in oral presentation supports advancement to pivotal study – – Single agent activity and long-term treatment duration demonstrated– SAN LEANDRO, Calif., February 15, 2019—Rainier Therapeutics, Inc., a privately-held clinical s... read more

Thursday, February 14, 2019 Oslo, Norway, 14 February 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter and full year 2018 results. A meeting for investors, analysts ... read more

THU, FEB 14, 2019 07:30 CET OCT - DEC Net sales increased by 53% to SEK 62.2m (40.6). Adjusted for currency exchange rate effects, the increase was 44% Operating profit increased to SEK 28.7m (14.6). Operating profit includes litigation costs of SEK 0.1m (4.1) relating to the company... read more

Mölndal, February 13, 2019 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the year-end report for 2018. The year-end report will be published on March 15, 2019, instead of previously announced February 22, 2019. The reason for postponing the report is the decision ... read more